查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602363

肢端肥大症治療市場：依疾病類型、藥物類別、通路、最終用戶分類 - 2025-2030 年全球預測

Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肢端肥大症治療市值為24.8億美元，預計2024年將達27.2億美元，複合年成長率為9.92%，預計到2030年將達到48.1億美元。

肢端肥大症是一種罕見的荷爾蒙失調，其特徵是生長激素分泌過多，通常由腦下垂體良性腫瘤引起。肢端肥大症的治療包括藥物、手術和放射線治療，旨在降低生長激素水平並緩解症狀。肢端肥大症治療的市場需求凸顯，因為這種疾病如果不及時治療可能會導致嚴重的健康併發症，因此早期診斷和介入至關重要。應用主要是內分泌診所和專業醫療機構，由於疾病的慢性性質，最終用途主要用於藥物干預。

主要市場統計
基準年[2023] 24.8億美元
預測年份 [2024] 27.2億美元
預測年份 [2030] 48.1億美元
複合年成長率（%） 9.92%

推動市場成長的關鍵因素包括對罕見荷爾蒙疾病的認知不斷提高、診斷技術的進步以及新型藥物治療的開拓。生技藥品和胜肽製劑的技術創新以及外科技術的突破帶來了巨大的商機。隨著微創治療方法的引入和藥物傳輸系統的改進，市場環境可能會進一步加強。然而，高昂的治療成本、由於罕見疾病而導致的患者數量有限以及當前治療方法的潛在副作用等挑戰是市場擴張的障礙。此外，監管障礙和漫長的核准流程可能會減緩新治療方法的推出。

利用成長機會的研究包括投資研發以創造更有效、侵入性更小的治療方法，以及擴展到意識和診斷率不斷提高的新興市場。生物技術公司與醫學研究機構之間的合作加速了創新。創新和研究的最佳領域包括開發個人化醫療方法以及探索細胞療法和基因編輯技術，以從根本上解決肢端肥大症。市場動態是動態的、創新主導的，需要專注於前沿研究和策略夥伴關係關係，以克服複雜性並充分發揮潛力。

市場動態：快速發展的肢端肥大症治療市場的關鍵市場洞察

肢端肥大症治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 世界各地遺傳和荷爾蒙疾病的流行
    • 提高對肢端肥大症診斷與治療的認知
    • 採用外科手術及放射線治療治療肢端肥大症
  • 市場限制因素
    • 肢端肥大症治療高成本且發生藥品召回
  • 市場機會
    • 肢端肥大症新藥物製劑及給藥途徑的開發
    • 核准荷爾蒙療法治療肢端肥大症
  • 市場挑戰
    • 與藥物治療相關的副作用

波特五力：駕馭肢端肥大症治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肢端肥大症治療市場的外在影響

外部宏觀環境因素在塑造肢端肥大症治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肢端肥大症治療市場的競爭狀況

對肢端肥大症治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣肢端肥大症治療市場供應商的表現評估

FPNV定位矩陣是評估肢端肥大症治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製肢端肥大症治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，肢端肥大症治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 遺傳和荷爾蒙疾病的全球盛行率
      • 提高對肢端肥大症診斷與治療的認知
      • 採用手術和放射線治療治療肢端肥大症
    • 抑制因素
      • 肢端肥大症治療費用高且藥品回收發生率高
    • 機會
      • 肢端肥大症新藥物製劑及給藥途徑的開發
      • 核准荷爾蒙療法治療肢端肥大症
    • 任務
      • 與藥物治療相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肢端肥大症治療市場：依疾病類型

  • 異位肢端肥大症
  • 假性肢端肥大症

第7章肢端肥大症治療市場（依藥物類別）

  • 甲磺酸溴隱亭（Parlodel）
  • 多巴胺促效劑
  • 生長激素受體拮抗劑
  • 生長抑制素類似物 (SSA)
  • Somatuline Depot（Lanreotide）
  • 索瑪巴特（培維索孟）

第8章肢端肥大症治療市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章肢端肥大症治療市場：依最終用戶分類

  • 門診手術中心
  • 家庭護理設置
  • 醫院/診所

第10章美洲肢端肥大症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太肢端肥大症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲肢端肥大症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Advanz Pharma Services（UK）Limited
  • Aetna Inc.
  • Amolyt Pharma SAS
  • Amryt Pharma PLC
  • Bayer AG
  • Biodexa Pharmaceuticals PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Foresee Pharmaceuticals Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Ionis Pharmaceuticals, Inc.
  • Ipsen Pharma
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Peptron Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Validus Pharmaceuticals LLC
  • Xeris Pharmaceuticals, Inc.
Product Code: MRR-742BD517A3A4

The Acromegaly Treatment Market was valued at USD 2.48 billion in 2023, expected to reach USD 2.72 billion in 2024, and is projected to grow at a CAGR of 9.92%, to USD 4.81 billion by 2030.

Acromegaly is a rare hormonal disorder characterized by the excessive production of growth hormone, typically caused by benign tumors on the pituitary gland. The treatment landscape for acromegaly includes medications, surgical procedures, and radiation therapies designed to reduce growth hormone levels and mitigate symptoms. Market necessity for acromegaly treatments is underscored by the condition's potential to cause serious health complications if left unmanaged, making early diagnosis and intervention crucial. The application is primarily in endocrine clinics and specialized healthcare facilities, with pharmaceutical interventions being the primary end-use focus due to the chronic nature of the condition.

KEY MARKET STATISTICS
Base Year [2023] USD 2.48 billion
Estimated Year [2024] USD 2.72 billion
Forecast Year [2030] USD 4.81 billion
CAGR (%) 9.92%

Key factors driving market growth include rising awareness of rare hormonal disorders, advancements in diagnostic technologies, and the development of novel pharmacological treatments. Innovations in biologics and peptide-based formulations, as well as breakthroughs in surgical techniques, present significant opportunities. The introduction of less invasive treatment options and improved drug delivery systems could further enhance the market landscape. However, challenges such as high treatment costs, limited patient populations due to the rarity of the disease, and potential side effects of current therapies pose barriers to market expansion. Additionally, regulatory hurdles and lengthy approval processes can delay the introduction of new treatments.

Recommendations for leveraging growth opportunities include investing in research and development to create more effective, less invasive treatments and expanding into emerging markets where awareness and diagnosis rates are increasing. Collaborations between biotech firms and medical research institutions can accelerate innovation. Best areas of innovation and research include developing personalized medicine approaches and exploring cell therapy or gene editing technologies to address acromegaly at its root. The acromegaly treatment market is dynamic and innovation-driven, necessitating a focus on cutting-edge research and strategic partnerships to navigate its complexities and realize its potential fully.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acromegaly Treatment Market

The Acromegaly Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of genetic & hormonal diseases worldwide
    • Rising awareness regarding acromegaly diagnosis & treatment
    • Adoption of surgical procedures and radiation therapies for acromegaly treatment
  • Market Restraints
    • High cost of acromegaly treatment and incidences of drug recalls
  • Market Opportunities
    • Development of new acromegaly drug formulations and route of administration
    • Hormone therapy approvals for acromegaly treatments
  • Market Challenges
    • Side effects associated with drug treatments

Porter's Five Forces: A Strategic Tool for Navigating the Acromegaly Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acromegaly Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acromegaly Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acromegaly Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acromegaly Treatment Market

A detailed market share analysis in the Acromegaly Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acromegaly Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acromegaly Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acromegaly Treatment Market

A strategic analysis of the Acromegaly Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acromegaly Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Services (UK) Limited, Aetna Inc., Amolyt Pharma SAS, Amryt Pharma PLC, Bayer AG, Biodexa Pharmaceuticals PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Crinetics Pharmaceuticals, Inc., DexTech Medical AB, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Foresee Pharmaceuticals Co., Ltd., Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals, Inc., Ipsen Pharma, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Peptron Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, and Xeris Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Acromegaly Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Ectopic Acromegaly and Pseudo Acromegaly.
  • Based on Drug Class, market is studied across Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist, Somatostatin Analogs (SSAs), Somatuline Depot (Lanreotide), and Somavert (Pegvisomant).
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Settings, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of genetic & hormonal diseases worldwide
      • 5.1.1.2. Rising awareness regarding acromegaly diagnosis & treatment
      • 5.1.1.3. Adoption of surgical procedures and radiation therapies for acromegaly treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of acromegaly treatment and incidences of drug recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of new acromegaly drug formulations and route of administration
      • 5.1.3.2. Hormone therapy approvals for acromegaly treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with drug treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acromegaly Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Ectopic Acromegaly
  • 6.3. Pseudo Acromegaly

7. Acromegaly Treatment Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Bromocriptine Mesylate (Parlodel)
  • 7.3. Dopamine Agonists
  • 7.4. Growth Hormone Receptor Antagonist
  • 7.5. Somatostatin Analogs (SSAs)
  • 7.6. Somatuline Depot (Lanreotide)
  • 7.7. Somavert (Pegvisomant)

8. Acromegaly Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Acromegaly Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Homecare Settings
  • 9.4. Hospitals & Clinics

10. Americas Acromegaly Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acromegaly Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acromegaly Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Advanz Pharma Services (UK) Limited
  • 3. Aetna Inc.
  • 4. Amolyt Pharma SAS
  • 5. Amryt Pharma PLC
  • 6. Bayer AG
  • 7. Biodexa Pharmaceuticals PLC
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb Company
  • 10. Crinetics Pharmaceuticals, Inc.
  • 11. DexTech Medical AB
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. Foresee Pharmaceuticals Co., Ltd.
  • 15. Hikma Pharmaceuticals PLC
  • 16. Ionis Pharmaceuticals, Inc.
  • 17. Ipsen Pharma
  • 18. Lupin Pharmaceuticals, Inc.
  • 19. Merck & Co., Inc.
  • 20. Mylan N.V.
  • 21. Novartis AG
  • 22. Peptron Inc.
  • 23. Pfizer Inc.
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Validus Pharmaceuticals LLC
  • 26. Xeris Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. ACROMEGALY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ACROMEGALY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACROMEGALY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACROMEGALY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACROMEGALY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACROMEGALY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY ECTOPIC ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY PSEUDO ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY BROMOCRIPTINE MESYLATE (PARLODEL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY GROWTH HORMONE RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY SOMATOSTATIN ANALOGS (SSAS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY SOMATULINE DEPOT (LANREOTIDE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY SOMAVERT (PEGVISOMANT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. ACROMEGALY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ACROMEGALY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023